A Mosaic Nanoparticle Vaccine Elicits Potent Mucosal Immune Response with Significant Cross‐Protection Activity against Multiple SARS‐CoV‐2 Sublineages
Abstract Because of the rapid mutation and high airborne transmission of SARS‐CoV‐2, a universal vaccine preventing the infection in the upper respiratory tract is particularly urgent. Here, a mosaic receptor‐binding domain (RBD) nanoparticle (NP) vaccine is developed, which induces more RBD‐targete...
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-09-01
|
| Series: | Advanced Science |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/advs.202301034 |
| _version_ | 1797673987543662592 |
|---|---|
| author | Xiantao Zhang Shijian Wu Jie Liu Ran Chen Yongli Zhang Yingtong Lin Zhihui Xi Jieyi Deng Zeyu Pu Chaofeng Liang Jinzhu Feng Rong Li Keming Lin Mo Zhou Yingying Liu Xu Zhang Bingfeng Liu Yiwen Zhang Xin He Hui Zhang |
| author_facet | Xiantao Zhang Shijian Wu Jie Liu Ran Chen Yongli Zhang Yingtong Lin Zhihui Xi Jieyi Deng Zeyu Pu Chaofeng Liang Jinzhu Feng Rong Li Keming Lin Mo Zhou Yingying Liu Xu Zhang Bingfeng Liu Yiwen Zhang Xin He Hui Zhang |
| author_sort | Xiantao Zhang |
| collection | DOAJ |
| description | Abstract Because of the rapid mutation and high airborne transmission of SARS‐CoV‐2, a universal vaccine preventing the infection in the upper respiratory tract is particularly urgent. Here, a mosaic receptor‐binding domain (RBD) nanoparticle (NP) vaccine is developed, which induces more RBD‐targeted type IV neutralizing antibodies (NAbs) and exhibits broad cross‐protective activity against multiple SARS‐CoV‐2 sublineages including the newly‐emerged BF.7, BQ.1, XBB. As several T‐cell‐reactive epitopes, which are highly conserved in sarbecoviruses, are displayed on the NP surface, it also provokes potent and cross‐reactive cellular immune responses in the respiratory tissue. Through intranasal delivery, it elicits robust mucosal immune responses and full protection without any adjuvants. Therefore, this intranasal mosaic NP vaccine can be further developed as a pan‐sarbecovirus vaccine to block the viral entrance from the upper respiratory tract. |
| first_indexed | 2024-03-11T21:52:33Z |
| format | Article |
| id | doaj.art-5a261decdfe94b549268ee1651b4491d |
| institution | Directory Open Access Journal |
| issn | 2198-3844 |
| language | English |
| last_indexed | 2024-03-11T21:52:33Z |
| publishDate | 2023-09-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advanced Science |
| spelling | doaj.art-5a261decdfe94b549268ee1651b4491d2023-09-26T07:39:32ZengWileyAdvanced Science2198-38442023-09-011027n/an/a10.1002/advs.202301034A Mosaic Nanoparticle Vaccine Elicits Potent Mucosal Immune Response with Significant Cross‐Protection Activity against Multiple SARS‐CoV‐2 SublineagesXiantao Zhang0Shijian Wu1Jie Liu2Ran Chen3Yongli Zhang4Yingtong Lin5Zhihui Xi6Jieyi Deng7Zeyu Pu8Chaofeng Liang9Jinzhu Feng10Rong Li11Keming Lin12Mo Zhou13Yingying Liu14Xu Zhang15Bingfeng Liu16Yiwen Zhang17Xin He18Hui Zhang19Institute of Human Virology Department of Pathogen Biology and Biosecurity Key Laboratory of Tropical Disease Control of Ministry of Education Zhongshan School of Medicine Sun Yat‐sen University Guangzhou 510080 ChinaInstitute of Human Virology Department of Pathogen Biology and Biosecurity Key Laboratory of Tropical Disease Control of Ministry of Education Zhongshan School of Medicine Sun Yat‐sen University Guangzhou 510080 ChinaInstitute of Human Virology Department of Pathogen Biology and Biosecurity Key Laboratory of Tropical Disease Control of Ministry of Education Zhongshan School of Medicine Sun Yat‐sen University Guangzhou 510080 ChinaInstitute of Human Virology Department of Pathogen Biology and Biosecurity Key Laboratory of Tropical Disease Control of Ministry of Education Zhongshan School of Medicine Sun Yat‐sen University Guangzhou 510080 ChinaInstitute of Human Virology Department of Pathogen Biology and Biosecurity Key Laboratory of Tropical Disease Control of Ministry of Education Zhongshan School of Medicine Sun Yat‐sen University Guangzhou 510080 ChinaInstitute of Human Virology Department of Pathogen Biology and Biosecurity Key Laboratory of Tropical Disease Control of Ministry of Education Zhongshan School of Medicine Sun Yat‐sen University Guangzhou 510080 ChinaInstitute of Human Virology Department of Pathogen Biology and Biosecurity Key Laboratory of Tropical Disease Control of Ministry of Education Zhongshan School of Medicine Sun Yat‐sen University Guangzhou 510080 ChinaInstitute of Human Virology Department of Pathogen Biology and Biosecurity Key Laboratory of Tropical Disease Control of Ministry of Education Zhongshan School of Medicine Sun Yat‐sen University Guangzhou 510080 ChinaInstitute of Human Virology Department of Pathogen Biology and Biosecurity Key Laboratory of Tropical Disease Control of Ministry of Education Zhongshan School of Medicine Sun Yat‐sen University Guangzhou 510080 ChinaInstitute of Human Virology Department of Pathogen Biology and Biosecurity Key Laboratory of Tropical Disease Control of Ministry of Education Zhongshan School of Medicine Sun Yat‐sen University Guangzhou 510080 ChinaInstitute of Human Virology Department of Pathogen Biology and Biosecurity Key Laboratory of Tropical Disease Control of Ministry of Education Zhongshan School of Medicine Sun Yat‐sen University Guangzhou 510080 ChinaInstitute of Human Virology Department of Pathogen Biology and Biosecurity Key Laboratory of Tropical Disease Control of Ministry of Education Zhongshan School of Medicine Sun Yat‐sen University Guangzhou 510080 ChinaInstitute of Human Virology Department of Pathogen Biology and Biosecurity Key Laboratory of Tropical Disease Control of Ministry of Education Zhongshan School of Medicine Sun Yat‐sen University Guangzhou 510080 ChinaInstitute of Human Virology Department of Pathogen Biology and Biosecurity Key Laboratory of Tropical Disease Control of Ministry of Education Zhongshan School of Medicine Sun Yat‐sen University Guangzhou 510080 ChinaInstitute of Human Virology Department of Pathogen Biology and Biosecurity Key Laboratory of Tropical Disease Control of Ministry of Education Zhongshan School of Medicine Sun Yat‐sen University Guangzhou 510080 ChinaInstitute of Human Virology Department of Pathogen Biology and Biosecurity Key Laboratory of Tropical Disease Control of Ministry of Education Zhongshan School of Medicine Sun Yat‐sen University Guangzhou 510080 ChinaInstitute of Human Virology Department of Pathogen Biology and Biosecurity Key Laboratory of Tropical Disease Control of Ministry of Education Zhongshan School of Medicine Sun Yat‐sen University Guangzhou 510080 ChinaInstitute of Human Virology Department of Pathogen Biology and Biosecurity Key Laboratory of Tropical Disease Control of Ministry of Education Zhongshan School of Medicine Sun Yat‐sen University Guangzhou 510080 ChinaInstitute of Human Virology Department of Pathogen Biology and Biosecurity Key Laboratory of Tropical Disease Control of Ministry of Education Zhongshan School of Medicine Sun Yat‐sen University Guangzhou 510080 ChinaInstitute of Human Virology Department of Pathogen Biology and Biosecurity Key Laboratory of Tropical Disease Control of Ministry of Education Zhongshan School of Medicine Sun Yat‐sen University Guangzhou 510080 ChinaAbstract Because of the rapid mutation and high airborne transmission of SARS‐CoV‐2, a universal vaccine preventing the infection in the upper respiratory tract is particularly urgent. Here, a mosaic receptor‐binding domain (RBD) nanoparticle (NP) vaccine is developed, which induces more RBD‐targeted type IV neutralizing antibodies (NAbs) and exhibits broad cross‐protective activity against multiple SARS‐CoV‐2 sublineages including the newly‐emerged BF.7, BQ.1, XBB. As several T‐cell‐reactive epitopes, which are highly conserved in sarbecoviruses, are displayed on the NP surface, it also provokes potent and cross‐reactive cellular immune responses in the respiratory tissue. Through intranasal delivery, it elicits robust mucosal immune responses and full protection without any adjuvants. Therefore, this intranasal mosaic NP vaccine can be further developed as a pan‐sarbecovirus vaccine to block the viral entrance from the upper respiratory tract.https://doi.org/10.1002/advs.202301034broad neutralizing antibodymosaic nanoparticle vaccinemucosal immune responsesSARS‐CoV‐2universal vaccines |
| spellingShingle | Xiantao Zhang Shijian Wu Jie Liu Ran Chen Yongli Zhang Yingtong Lin Zhihui Xi Jieyi Deng Zeyu Pu Chaofeng Liang Jinzhu Feng Rong Li Keming Lin Mo Zhou Yingying Liu Xu Zhang Bingfeng Liu Yiwen Zhang Xin He Hui Zhang A Mosaic Nanoparticle Vaccine Elicits Potent Mucosal Immune Response with Significant Cross‐Protection Activity against Multiple SARS‐CoV‐2 Sublineages Advanced Science broad neutralizing antibody mosaic nanoparticle vaccine mucosal immune responses SARS‐CoV‐2 universal vaccines |
| title | A Mosaic Nanoparticle Vaccine Elicits Potent Mucosal Immune Response with Significant Cross‐Protection Activity against Multiple SARS‐CoV‐2 Sublineages |
| title_full | A Mosaic Nanoparticle Vaccine Elicits Potent Mucosal Immune Response with Significant Cross‐Protection Activity against Multiple SARS‐CoV‐2 Sublineages |
| title_fullStr | A Mosaic Nanoparticle Vaccine Elicits Potent Mucosal Immune Response with Significant Cross‐Protection Activity against Multiple SARS‐CoV‐2 Sublineages |
| title_full_unstemmed | A Mosaic Nanoparticle Vaccine Elicits Potent Mucosal Immune Response with Significant Cross‐Protection Activity against Multiple SARS‐CoV‐2 Sublineages |
| title_short | A Mosaic Nanoparticle Vaccine Elicits Potent Mucosal Immune Response with Significant Cross‐Protection Activity against Multiple SARS‐CoV‐2 Sublineages |
| title_sort | mosaic nanoparticle vaccine elicits potent mucosal immune response with significant cross protection activity against multiple sars cov 2 sublineages |
| topic | broad neutralizing antibody mosaic nanoparticle vaccine mucosal immune responses SARS‐CoV‐2 universal vaccines |
| url | https://doi.org/10.1002/advs.202301034 |
| work_keys_str_mv | AT xiantaozhang amosaicnanoparticlevaccineelicitspotentmucosalimmuneresponsewithsignificantcrossprotectionactivityagainstmultiplesarscov2sublineages AT shijianwu amosaicnanoparticlevaccineelicitspotentmucosalimmuneresponsewithsignificantcrossprotectionactivityagainstmultiplesarscov2sublineages AT jieliu amosaicnanoparticlevaccineelicitspotentmucosalimmuneresponsewithsignificantcrossprotectionactivityagainstmultiplesarscov2sublineages AT ranchen amosaicnanoparticlevaccineelicitspotentmucosalimmuneresponsewithsignificantcrossprotectionactivityagainstmultiplesarscov2sublineages AT yonglizhang amosaicnanoparticlevaccineelicitspotentmucosalimmuneresponsewithsignificantcrossprotectionactivityagainstmultiplesarscov2sublineages AT yingtonglin amosaicnanoparticlevaccineelicitspotentmucosalimmuneresponsewithsignificantcrossprotectionactivityagainstmultiplesarscov2sublineages AT zhihuixi amosaicnanoparticlevaccineelicitspotentmucosalimmuneresponsewithsignificantcrossprotectionactivityagainstmultiplesarscov2sublineages AT jieyideng amosaicnanoparticlevaccineelicitspotentmucosalimmuneresponsewithsignificantcrossprotectionactivityagainstmultiplesarscov2sublineages AT zeyupu amosaicnanoparticlevaccineelicitspotentmucosalimmuneresponsewithsignificantcrossprotectionactivityagainstmultiplesarscov2sublineages AT chaofengliang amosaicnanoparticlevaccineelicitspotentmucosalimmuneresponsewithsignificantcrossprotectionactivityagainstmultiplesarscov2sublineages AT jinzhufeng amosaicnanoparticlevaccineelicitspotentmucosalimmuneresponsewithsignificantcrossprotectionactivityagainstmultiplesarscov2sublineages AT rongli amosaicnanoparticlevaccineelicitspotentmucosalimmuneresponsewithsignificantcrossprotectionactivityagainstmultiplesarscov2sublineages AT keminglin amosaicnanoparticlevaccineelicitspotentmucosalimmuneresponsewithsignificantcrossprotectionactivityagainstmultiplesarscov2sublineages AT mozhou amosaicnanoparticlevaccineelicitspotentmucosalimmuneresponsewithsignificantcrossprotectionactivityagainstmultiplesarscov2sublineages AT yingyingliu amosaicnanoparticlevaccineelicitspotentmucosalimmuneresponsewithsignificantcrossprotectionactivityagainstmultiplesarscov2sublineages AT xuzhang amosaicnanoparticlevaccineelicitspotentmucosalimmuneresponsewithsignificantcrossprotectionactivityagainstmultiplesarscov2sublineages AT bingfengliu amosaicnanoparticlevaccineelicitspotentmucosalimmuneresponsewithsignificantcrossprotectionactivityagainstmultiplesarscov2sublineages AT yiwenzhang amosaicnanoparticlevaccineelicitspotentmucosalimmuneresponsewithsignificantcrossprotectionactivityagainstmultiplesarscov2sublineages AT xinhe amosaicnanoparticlevaccineelicitspotentmucosalimmuneresponsewithsignificantcrossprotectionactivityagainstmultiplesarscov2sublineages AT huizhang amosaicnanoparticlevaccineelicitspotentmucosalimmuneresponsewithsignificantcrossprotectionactivityagainstmultiplesarscov2sublineages AT xiantaozhang mosaicnanoparticlevaccineelicitspotentmucosalimmuneresponsewithsignificantcrossprotectionactivityagainstmultiplesarscov2sublineages AT shijianwu mosaicnanoparticlevaccineelicitspotentmucosalimmuneresponsewithsignificantcrossprotectionactivityagainstmultiplesarscov2sublineages AT jieliu mosaicnanoparticlevaccineelicitspotentmucosalimmuneresponsewithsignificantcrossprotectionactivityagainstmultiplesarscov2sublineages AT ranchen mosaicnanoparticlevaccineelicitspotentmucosalimmuneresponsewithsignificantcrossprotectionactivityagainstmultiplesarscov2sublineages AT yonglizhang mosaicnanoparticlevaccineelicitspotentmucosalimmuneresponsewithsignificantcrossprotectionactivityagainstmultiplesarscov2sublineages AT yingtonglin mosaicnanoparticlevaccineelicitspotentmucosalimmuneresponsewithsignificantcrossprotectionactivityagainstmultiplesarscov2sublineages AT zhihuixi mosaicnanoparticlevaccineelicitspotentmucosalimmuneresponsewithsignificantcrossprotectionactivityagainstmultiplesarscov2sublineages AT jieyideng mosaicnanoparticlevaccineelicitspotentmucosalimmuneresponsewithsignificantcrossprotectionactivityagainstmultiplesarscov2sublineages AT zeyupu mosaicnanoparticlevaccineelicitspotentmucosalimmuneresponsewithsignificantcrossprotectionactivityagainstmultiplesarscov2sublineages AT chaofengliang mosaicnanoparticlevaccineelicitspotentmucosalimmuneresponsewithsignificantcrossprotectionactivityagainstmultiplesarscov2sublineages AT jinzhufeng mosaicnanoparticlevaccineelicitspotentmucosalimmuneresponsewithsignificantcrossprotectionactivityagainstmultiplesarscov2sublineages AT rongli mosaicnanoparticlevaccineelicitspotentmucosalimmuneresponsewithsignificantcrossprotectionactivityagainstmultiplesarscov2sublineages AT keminglin mosaicnanoparticlevaccineelicitspotentmucosalimmuneresponsewithsignificantcrossprotectionactivityagainstmultiplesarscov2sublineages AT mozhou mosaicnanoparticlevaccineelicitspotentmucosalimmuneresponsewithsignificantcrossprotectionactivityagainstmultiplesarscov2sublineages AT yingyingliu mosaicnanoparticlevaccineelicitspotentmucosalimmuneresponsewithsignificantcrossprotectionactivityagainstmultiplesarscov2sublineages AT xuzhang mosaicnanoparticlevaccineelicitspotentmucosalimmuneresponsewithsignificantcrossprotectionactivityagainstmultiplesarscov2sublineages AT bingfengliu mosaicnanoparticlevaccineelicitspotentmucosalimmuneresponsewithsignificantcrossprotectionactivityagainstmultiplesarscov2sublineages AT yiwenzhang mosaicnanoparticlevaccineelicitspotentmucosalimmuneresponsewithsignificantcrossprotectionactivityagainstmultiplesarscov2sublineages AT xinhe mosaicnanoparticlevaccineelicitspotentmucosalimmuneresponsewithsignificantcrossprotectionactivityagainstmultiplesarscov2sublineages AT huizhang mosaicnanoparticlevaccineelicitspotentmucosalimmuneresponsewithsignificantcrossprotectionactivityagainstmultiplesarscov2sublineages |